In a 2013 publication, Gill et.al. sought to examine two things: the patterns of utilization of hypothermic machine perfusion (HMP) as a function of cold ischemic time (CIT) and donor type as well as the impact of HMP on the risk of DGF by CIT and donor type. They used data from the Scientific Registry of Transplant Recipients (SRTR) on all adult deceased donor kidney transplant recipients between January 1, 2000 and December 1, 2011 to complete their analysis.
The overall results of the analysis were:
- In standard criteria donors (SCD)
- The odds of DGF were lower with HMP compared to CS at all CIT
- In extended criteria donors (ECD)
- HMP use was associated with reduced risk of DGF when CIT is beyond 6 hours
- In donation after circulatory death (DCD) donors
- HMP use was associated with reduced risk of DGF when the CIT is between 6 and 24 hours
They summarized that their data confirmed the benefits of HMP use in reducing the risk of DGF irrespective of the donor type and CIT. They concluded that the best strategy to reduce the risk of DGF if to use HMP and minimize CIT in all deceased donor kidney transplants.
Read the full article here: https://doi.org/10.1097/01.tp.0000438637.29214.10
Check out the most recent posts
In this article, Intermountain Healthcare transplant surgeons perform the first ever liver transplants in Utah with organs preserved by the LifePort® Liver Transporter during the clinical trial, PILOT™. PILOT (Perfusion to Improve Liver Outcomes in...
In this article from FOX19 NOW, meet the first liver transplant patient to receive a cold pump liver which was pumped on a LifePort® Liver Transporter during its clinical trial, PILOT™. PILOT (Perfusion to Improve Liver Outcomes in Transplantation) is a...
In this article, Intermountain Healthcare takes part in the PILOT™ clinical trial of the LifePort® Liver Transporter. PILOT (Perfusion to Improve Liver Outcomes in Transplantation) is a prospective randomized multi-center oxygenated hypothermic machine...
In this article, KSLTV of Salt Lake City reports on Intermountain Healthcare’s participation in the LifePort Liver Transporter clinical trial. “We’re keeping that liver working in a somewhat normal, physiologic state during the time that it’s out of the donor’s body...